{
  "docId": "019de518-6502-70bc-9a44-c6a9c7f323b5",
  "docSlug": "4230ce80abe7092521a593effe59cbcd",
  "documentTitle": "Oculis | Investor Presentation Deck | 48 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 48,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 48,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de518-6502-70bc-9a44-c6a9c7f323b5/17",
  "deckHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5",
  "deckJsonHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5.json",
  "deckAnchorHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.44,
        "x": 0.525,
        "y": 0.666
      },
      "kind": "list",
      "text": "Minimal mean IOP increase was similar across induction and maintenance phases",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12d8418a-0b43-4446-b447-8aa8bfccdaee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.44,
        "x": 0.525,
        "y": 0.578
      },
      "kind": "list",
      "text": "IOP increase consistent with literature",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "229d4682-c941-4a27-a97e-13ea2ae38959",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.44,
        "x": 0.525,
        "y": 0.49
      },
      "kind": "list",
      "text": "No evidence of cataract formation up to 12 weeks",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54c28af3-5d46-487e-8917-f5b17bd384fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.44,
        "x": 0.525,
        "y": 0.402
      },
      "kind": "list",
      "text": "None of the SAEs reported were deemed related to study drug",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be0cf534-69f4-4905-829f-dfeb1ddfaf47",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.13,
        "x": 0.028,
        "y": 0.878
      },
      "kind": "paragraph",
      "text": "Safety population",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dcc25a40-7307-492f-9d46-fe50dea63204",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.028,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "AE (Adverse event); IOP (Intraocular pressure); SAE (Serious adverse event); TEAE (Treatment-emergent adverse event).\nTadayoni R, et al. A 12-week phase 2/3 double-masked, randomized, multicenter study of OCS-01 OPTIREACH® technology topical dexamethasone eye drops in subjects with diabetic macular edema (DME): efficacy and safety findings.\nPresented at: EURETINA; 2023.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46564f0a-24fb-464e-b8fd-ef5c4bff5618",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.47,
        "x": 0.025,
        "y": 0.21
      },
      "kind": "table",
      "text": "Treatment-Emergent Adverse Events\n>2.0% in the OCS-01 arm or >4.0% in the vehicle arm\nOCS-01 (n=100) n (%)\nVehicle (n=48) n (%)\nAny TEAE 70 (70.0) 30 (62.5)\nDiabetic retinal edema 10 (10.0) 9 (18.8)\nIntraocular pressure increased 14 (14.0) 1 (2.1)\nHypertension 10 (10.0) 1 (2.1)\nOcular hypertension 8 (8.0) 0\nMacular edema 2 (2.0) 4 (8.3)\nCOVID-19 2 (2.0) 2 (4.2)\nDry eye 3 (3.0) 1 (2.1)\nDiabetes mellitus 3 (3.0) 0\nDizziness 3 (3.0) 0\nDysgeusia 3 (3.0) 0\nNasopharyngitis 2 (2.0) 1 (2.1)\nType 2 diabetes 2 (2.0) 1 (2.1)\nVisual acuity reduced 1 (1.0) 2 (4.2)\nVitreous haemorrhage 2 (2.0) 1 (2.1)\nArthralgia 2 (2.0) 0\nBlood glucose increased 2 (2.0) 0",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cf0683d-f040-42c1-b8df-2ee6ab931d51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.47,
        "x": 0.508,
        "y": 0.21
      },
      "kind": "table",
      "text": "Treatment-Emergent Serious Adverse Events\nOCS-01 (n=100) n (%)\nVehicle (n=48) n (%)\nAny ocular SAE 1 (1.0) 0 (0.0)\nVitreous hemorrhage 1 (1.0) 0 (0.0)\nAny non-ocular SAE 4 (4.0) 3 (6.3)\nDeath 1 (1.0) 0 (0.0)",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24b93be6-09ad-48ae-91aa-9e1d92bfbdb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.54,
        "x": 0.108,
        "y": 0.14
      },
      "kind": "title",
      "text": "Well-tolerated with no unexpected AEs",
      "attrs": {},
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "759d7b88-d8d3-4b5a-9db4-76876df708f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.67,
        "x": 0.028,
        "y": 0.044
      },
      "kind": "title",
      "text": "5 Key Takeaways From OCS-01 DIAMOND Stage 1",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7213e38c-0e7a-493f-89a7-7b7a236e6eaf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}